Overview

Symptom Improvements in Gastroesophageal Reflux Disease (GERD) Patients

Status:
Completed
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate the effect of AZD3355 as an add-on treatment to a Proton Pump Inhibitor (PPI) on Gastroesophageal reflux disease (GERD) symptoms in patients with an incomplete response to PPI treatment.
Phase:
Phase 2
Details
Lead Sponsor:
AstraZeneca
Treatments:
Lesogaberan
Proton Pump Inhibitors